Tumor necrosis factor-α-308 gene polymorphism is associated with synthetic hemodialysis graft failure

Journal of Investigative Medicine

Volumn 51, Issue 1, 2003, Pages 19-26

  Ram, Sunanda ^a   Bass, Kristen ^b   Abreo, Ken ^a   Baier, R John ^a   Kruger, Thomas E ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b NONE

Author keywords

Cytokine gene polymorphisms; Hemodialysis; Polytetrafluoroethylene graft; Tumor necrosis factor

Indexed keywords

CYTOKINE; POLITEF; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENOTYPE; GRAFT FAILURE; GRAFT SURVIVAL; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; THROMBOSIS;

EID: 0037291665     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042871-200302000-00023     Document Type: Article

References (54)

1. Zibari GB, McDonald JC. Hemodialysis vascular access: a transplant surgeon's perspective. In: Trerotola SA, editor. Venous interventional radiology. New York: Thieme Medical Publishers; 2000. p. 223-30.
2. US Renal Data System. USRDS 1997. Annual Data Report. Bethesda, MD: Institute of Diabetes and Digestive and Kidney Disease. NIH. 45-47.
3. Hakim R, Himmelfarb J. Hemodialysis access failure: a call to action. Kidney Int 1998;54:1029-40.
4. Miller PE, Carlton D, Deierhoi MH, et al. Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis 2000;36:68-74.
5. Zaman F, Ram SJ, Dixit A, et al. Early hemodialysis graft thrombosis is associated with stenosis at the venous anastomosis. J Am Soc Nephrol 1999;10:223A.
6. Allon M, Lockhart ME, Lilly RZ, et al. Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients. Kidney Int 2001;60:2013-20.
7. Alberta JA, Auger KR, Batt D, et al. Platelet-derived growth factor stimulation of monocyte chemoattractant protein-1 gene expression is mediated by transient activation of the phosphoinositide 3-kinase signal transduction pathway. J Biol Chem 1999;27:31062-7.
8. Wempe F, Lindner V, Augustin HG. Basic fibroblast growth factor (bFGF) regulates the expression of the CC chemokine monocyte chemoattractant protein-1 (MCP-1) in autocrine-activated endothelial cells. Arterioscler Thromb Vasc Biol 1997;17:2471-8.
9. Stuhlmeier KM, Tarn C, CsizmadiaV, Bach FH. Selective suppression of endothelial cell activation by arachidonic acid. Eur J Immunol 1996;26:1417-23.
10. Wysocki SJ, Zheng MH, Smith A, et al. Monocyte chemoattractant protein-1 gene expression in injured pig artery coincides with early appearance of infiltrating monocyte/macrophages. J Cell Biochem 1996;62:303-13.
11. Humphries J, McGuinness CL, Smith A, et al. Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. J Vasc Surg 1999;30:894-9.
12. Abbott KL, Robida AM, Davis ME, et al. Differential regulation of vascular smooth muscle nuclear factor kappa-B by G alpha q-coupled and cytokine receptors. J Mol Cell Cardiol 2000;32:391-403.
13. De Keulenaer GW, Ushio-Fukai M, Yin Q, et al. Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factor-alpha-mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000;20:385-91.
14. Weber KS, Nelson PJ, Grone HJ, Weber C. Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and In vivo inflammatory activation of endothelium. Arterioscler Thromb Vasc Biol 1999;19:2085-93.
15. Scott-Burden T, Schini VB, Elizondo E, et al. Platelet-derived growth factor suppresses and fibroblast growth factor enhances cytokine-induced production of nitric oxide by cultured smooth muscle cells. Effects on cell proliferation. Circ Res 1992;71:1088-100.
16. Hanada M, Saito E, Kambe T, et al. Evidence for the involvement of platelet-derived growth factor in the angiotensin II-induced growth of rat vascular smooth muscle cells. Biol Pharm Bull 1999;22:137-41.
17. Chen YM, Wu KD, Tsai TJ, Hsieh BS. Pentoxifylline inhibits PDGF-induced proliferation of and TGF-beta-stimulated collagen synthesis by vascular smooth muscle cells. J Mol Cell Cardiol 1999;31:773-83.
18. Rzucidlo EM, Quist WC, Hamdan AD, LoGerfo FW. Interferon gamma up-regulates a novel protein in vascular smooth muscle cells. J Vasc Surg 1999;29:317-23.
19. Sterpetti AV, CucinaA, Lepidi S, et al. Progression and regression of myointimal hyperplasia in experimental vein grafts depends on platelet-derived growth factor and basic fibroblastic growth factor production. J Vasc Surg 1996;23:568-75.
20. Hoch JR, Stark VK, Turnipseed WD. The temporal relationship between the development of vein graft intimal hyperplasia and growth factor gene expression. J Vasc Surg 1995;22:51-8.
21. Francis SE, Hunter S, Holt CM, et al. Release of platelet-derived growth factor activity from pig venous arterial grafts. J Thorac Cardiovasc Surg 1994;108:540-8.
22. Faries PL, Marin ML, Veith FJ, et al. Immunolocalization and temporal distribution of cytokine expression during the development of vein graft intimal hyperplasia in an experimental model. J Vasc Surg 1996;24:463-71.
23. O'Brien JE, Shi Y, Fard A, et al. Wound healing around and within saphenous vein bypass grafts. J Thorac Cardiovasc Surg 1997;114:38-45.
24. Sterpetti AV, Cucina A, Lepidi S, et al. Formation of myointimal hyperplasia and cytokine production in experimental vein grafts. Surgery 1998;123:461-9.
25. Dilley RJ, McGeachie JK, Tennant M. The role of cell proliferation and migration in the development of a neo-intimal layer in veins grafted into arteries, in rats. Cell Tissue Res 1992;269:281-7.
26. Golden MA, Au YP, Kenagy RD, Clowes AW. Growth factor gene expression by intimal cells in healing polytetrafluoroethylene grafts. J Vasc Surg 1990;11:580-5.
27. Kissin M, Kansal N, Pappas PJ, et al. Vein interposition cuffs decrease the intimal hyperplastic response of polytetrafluoroethylene bypass grafts. J Vasc Surg 2000;31(1 Pt 1):69-83.
28. Sapienza P, Di Marzo L, Cucina A, et al. Release of PDGF-BB and bFGF by human endothelial cells seeded on expanded polytetrafluoroethylene vascular grafts. J Surg Res 1998;75:24-9.
29. Stark VK, Hoch JR, Warner TF, Hullett DA. Monocyte chemotactic protein-1 expression is associated with the development of vein graft intimal hyperplasia. Arterioscler Thromb Vasc Biol 1997;17:1614-21.
30. Siegert A, Ritz E, Orth S, Wagner J. Differential regulation of transforming growth factor receptors by angiotensin II and transforming growth factor beta in vascular smooth muscle. J Mol Med 1999;77:437-45.
31. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type I receptor. Am J Respir Crit Care Med 2000;161:1999-2004.
32. Halloran BG, So BJ, Baxter BT. Platelet-derived growth factor is a cofactor in the induction of 1 alpha(I) procollagen expression by transforming growth factor-beta 1 in smooth muscle cells. J Vasc Surg 1996;23:767-73.
33. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000;97:8015-20.
34. Yamamoto K, Morishita R, Tomita N, et al. Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation 2000;102:1308-14.
35. Roy-Chaudhury R, Kelly BS, Miller MA, et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001;59:2325-34.
36. De Marchi S, Falleti E, Giacomello R, et al. Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol 1996;7:1169-77.
37. Sankaran D, Asderakis A, Ashraf S, et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int 1999;56:281-8.
38. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-γ, interleukin-10, transforming growth factor-β1 and tumor necrosis factor-α genes: a technical report. Transpl Immunol 1998;6:193-7.
39. Hutchinson IV, Pravica V, Perrey C, Sinnott P. Cytokine gene polymorphisms and relevance to forms of rejection. Transplant Proc 1999;31:734-6.
40. Hutchinson IV, Turner DM, Sankaran D, et al. Influence of cytokine genotypes on allograft rejection. Transplant Proc 1998;30:862-3.
41. Azzawi M, Grant SD, Hastleton PS, et al. TNF-α mRNA and protein in cardiac transplant biopsies: comparison with serum TNF-α levels. Cardiovasc Res 1996;32:551-6.
42. Coakley G, Mok CC, Hajeer AH, et al. Interleukin-10 promoter polymorphisms in rheumatoid arthritis and Felty's syndrome. Br J Rheumatol 1998;37:988-91.
43. Wilson AG, di Giovine FS, Duff GW. Genetics of tumour necrosis factor-α in autoimmune, infectious, and neoplastic diseases. J Inflamm 1995;45:1-12.
44. Turner DM, Grant SC, Lamb WR, et al. A genetic marker of high TNF-α production in heart transplant recipients. Transplantation 1995;60:1113-7.
45. Turner DM, Grant SC, Yonan N, et al. Cytokine gene polymorphism and heart transplant rejection. Transplantation 1997;64:776-9.
46. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis α promoter on transcription activation. Proc Natl Acad Sci U S A 1997;94:3195-9.
47. Haukim N, Bidwell JL, Smith AJ, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 2002;3 Suppl 2:313-30.
48. Wilson AG, di Giovine FS, Blakemore AI, Duff GW. Single base polymorphism in the human tumor necrosis factor alpha (TNFα) gene detectable by NcoI restriction of PCR product. Hum Mol Gene 1992;1:353.
49. Zhang M, Tracey KJ. In: Thomson AW, editor. The cytokine handbook. 3rd ed. San Diego (CA): Academic Press; 1998. p. 517-48.
50. Abbott KL, Robida AM, Davis ME, et al. Differential regulation of vascular smooth muscle nuclear factor kappa-B by G alpha q-coupled and cytokine receptors. J Mol Cell Cardiol 2000;32:391-403.
51. De Keulenaer GW, Ushio-Fukai M, Yin Q, et al. Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factor-alpha-mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000;20:385-91.
52. Wysocki SJ, Zheng MH, Smith A, et al. Monocyte chemoattractant protein-1 gene expression in injured pig artery coincides with early appearance of infiltrating monocyte/macrophages. J Cell Biochem 1996;62:303-13.
53. Stark VK, Hoch JR, Warner TF, Hullett DA. Monocyte chemotactic protein-1 expression is associated with the development of vein graft intimal hyperplasia. Arterioscler Thromb Vasc Biol 1997;17:1614-21.
54. Conway DJ, Holland MJ, Bailey RL, et al. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid. Infect Immun 1997;65:1003-6.